Regeneron and Mammoth collaborate on gene editing therapies
The collaboration will combine Regeneron's expertise in AAVs and antibodies with Mammoth's knowledge in compact gene editing to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Apr 24
The collaboration will combine Regeneron's expertise in AAVs and antibodies with Mammoth's knowledge in compact gene editing to…
25 Apr 24
Moderna will embed OpenAI’s generative AI tools throughout its organisation and adopt ChatGPT Enterprise to use Generative AI…
25 Apr 24
The approval was based on results from three controlled clinical trials of females aged 18 and above in…
25 Apr 24
The approval was based on the results from the Phase 3 PROTECT study which reached its primary endpoint…
24 Apr 24
The competing lawsuits over Covid-19 vaccines are a part of the ongoing litigation worldwide, centred around mRNA technology,…
24 Apr 24
Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential…
23 Apr 24
Emblaveo underwent review through the EMA accelerated assessment procedure, which is employed for pharmaceutical products deemed of significant…
23 Apr 24
Ipsen would acquire an exclusive global license to develop successful development candidates (DC), by paying up to $1.8bn…
23 Apr 24
The partnership agreement, which has the potential to earn more than $1bn for Ochre Bio, aims to discover…
23 Apr 24
The approval is for patients with BCG-unresponsive non-muscle invasive bladder cancer presenting carcinoma in situ, irrespective of papillary…